University of Birmingham: Patients With Atrial High-Rate Episodes Should Not Be Treated With Anticoagulant, Trial Finds
September 28, 2023
September 28, 2023
BIRMINGHAM, England, Sept. 28 (TNSres) -- The University of Birmingham issued the following news:
The NOAH-AFNET 6 trial shows that giving a direct oral anticoagulant to patients with these device-detected arrhythmias has no benefits and increases risks.
A trial involving Birmingham researchers showed that patients with atrial high-rate episodes (AHREs) detected by implanted cardiac devices, but no diagnosed atrial fibrillation (AF), have worse outcomes when given a dir . . .
The NOAH-AFNET 6 trial shows that giving a direct oral anticoagulant to patients with these device-detected arrhythmias has no benefits and increases risks.
A trial involving Birmingham researchers showed that patients with atrial high-rate episodes (AHREs) detected by implanted cardiac devices, but no diagnosed atrial fibrillation (AF), have worse outcomes when given a dir . . .
